6,483 results match your criteria Clinical Safety in Neurology


Pharmacologic Prevention and Treatment of Neonatal Brain Injury.

Clin Perinatol 2019 Jun 26;46(2):311-325. Epub 2019 Mar 26.

Fetal-Neonatal Neurology Program, Department of Neurology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA. Electronic address:

Neonatal brain injury (NBI) remains a major contributor to neonatal mortality and long-term neurodevelopmental morbidity. Although therapeutic hypothermia is the only proven treatment to minimize brain injury caused by neonatal encephalopathy in term neonates, it provides incomplete neuroprotection. There are no specific drugs yet proven to prevent NBI in preterm neonates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clp.2019.02.006DOI Listing

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.

Eur Stroke J 2016 Sep 3;1(3):146-154. Epub 2016 Aug 3.

Department of Medicine (Cardiology), Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada.

Background: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The stroke recurrence rate is substantial with aspirin, widely used for secondary prevention. The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic Stroke of Undetermined Source international trial will compare the efficacy and safety of rivaroxaban, an oral factor Xa inhibitor, versus aspirin for secondary prevention in patients with recent embolic strokes of undetermined source. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2396987316663049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301240PMC
September 2016

A pilot study on the efficacy of transcranial direct current stimulation applied to the pharyngeal motor cortex for dysphagia associated with brainstem involvement in multiple sclerosis.

Clin Neurophysiol 2019 Apr 11;130(6):1017-1024. Epub 2019 Apr 11.

Unit of Neurology and Neurorehabilitation, IRCCS Neuromed, Via Atinense 18, 86077 Pozzilli, IS, Italy.

Objective: we investigated the effect of anodal transcranial direct current stimulation (tDCS) applied over the pharyngeal motor area in dysphagia associated with multiple sclerosis (MS).

Methods: Eighteen MS patients with dysphagia associated with brainstem involvement were randomized to receive either "real" or "sham" tDCS.

Primary Outcome: The Penetration/Aspiration Scale (PAS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinph.2019.04.003DOI Listing

Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke.

Stroke 2019 May;50(5):1279-1281

Department of Neurosurgery (N.L.), Haukeland University Hospital, Bergen, Norway.

Background and Purpose- Tenecteplase represents a promising alternative to alteplase as thrombolytic treatment in acute ischemic stroke. There are limited data on tenecteplase 0.4 mg/kg in patients with increased stroke severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.119.025041DOI Listing
May 2019
1 Read

Efficacy of sertraline for post-stroke depression: A systematic review protocol of randomized controlled trial.

Medicine (Baltimore) 2019 Apr;98(16):e15299

Second Ward of Neurology Department, Cardiovascular and Cerebrovascular Specialist Section of Yan'an University Affiliated Hospital, Yan'an, China.

Background: Depression is a prevalent disorder for patients with stroke. Clinical researches indicate that sertraline is utilized to treat post-stroke depression (PSD) effectively. However, no systematic review has investigated this issue yet presently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000015299DOI Listing

Long-term health-related quality of life, survival and costs by different levels of functional outcome six months after stroke.

Eur Stroke J 2018 Jun 9;3(2):157-164. Epub 2018 Jan 9.

1Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Stockholm, Sweden.

Introduction: Information about the impact of functional outcome after stroke is currently missing on health-related quality of life, survival and costs. This information would be valuable for health economic evaluations and for allocation of resources in stroke health care.

Patients And Methods: Data on 297 Swedish patients included in the Third International Stroke Trial were analysed including functional outcome at six months (measured by Oxford Handicap Scale), health-related quality of life up to 18 months (EQ-5D-3L) and survival up to 36 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2396987317753444DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460413PMC

Endovascular treatment of acute basilar artery occlusion: Tama-REgistry of Acute Thrombectomy (TREAT) study.

J Neurol Sci 2019 Apr 12;401:29-33. Epub 2019 Apr 12.

Department of Stroke and Cerebrovascular Medicine, Kyorin University, Tokyo, Japan. Electronic address:

Objective: The effectiveness of mechanical thrombectomy (MT) for acute basilar artery occlusion (ABAO) remains unknown. We evaluated the feasibility, safety, and efficacy of endovascular treatment for ABAO.

Methods: We retrospectively investigated patients with ABAO who underwent MT, using modern stent retrievers and an aspiration device, between January 2015 and December 2017 at 12 comprehensive stroke centers. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022510X193016
Publisher Site
http://dx.doi.org/10.1016/j.jns.2019.04.010DOI Listing
April 2019
1 Read

Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.

Lancet 2019 Apr 17. Epub 2019 Apr 17.

Department of Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK. Electronic address:

Background: Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status epilepticus.

Methods: This open-label, randomised clinical trial was undertaken at 30 UK emergency departments at secondary and tertiary care centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)30724-XDOI Listing

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.

J Neurol Neurosurg Psychiatry 2019 Apr 19. Epub 2019 Apr 19.

Eli Lilly and Company, Indianapolis, Indiana, USA.

Background And Objective: As new migraine prevention treatments are developed, the onset of a preventive effect, how long it is maintained and whether patients initially non-responsive develop clinically meaningful responses with continued treatment can be assessed.

Methods: Analyses were conducted post-hoc of a double-blind, placebo-controlled, phase II-a study in patients with episodic migraine receiving galcanezumab 150 mg or placebo biweekly for 12 weeks ( 13:885, 2014). The number of migraine headache days per week, and onset of efficacy measured as the first week galacanezumab separated from placebo were determined. Read More

View Article

Download full-text PDF

Source
http://jnnp.bmj.com/lookup/doi/10.1136/jnnp-2018-320242
Publisher Site
http://dx.doi.org/10.1136/jnnp-2018-320242DOI Listing
April 2019
1 Read

Optimal Muscle Selection for OnabotulinumtoxinA Injections in Poststroke Lower-Limb Spasticity: A Randomized Trial.

Am J Phys Med Rehabil 2019 May;98(5):360-368

From the MossRehab Gait and Motion Analysis Laboratory, Elkins Park, Pennsylvania (AE); McGill University, Division of Neurology, Montreal General Hospital, Montreal, Quebec, Canada (THW); Staffordshire University, Faculty of Health and North Staffordshire Rehabilitation Centre, Haywood Hospital, Stoke-on-Trent, United Kingdom (ABW); Halifax Health, Brooks Rehabilitation, Daytona Beach, Florida (CG); Allergan plc, Bridgewater, New Jersey (CL); and Allergan plc, Irvine, California (RD).

Objective: The aim of the study was to identify optimal muscle selection patterns for onabotulinumtoxinA treatment of poststroke lower-limb spasticity.

Design: Adults with poststroke lower-limb spasticity (ankle Modified Ashworth Scale ≥3) were randomized to onabotulinumtoxinA (300 U, mandatory ankle plantar flexors; ≤100 U, optional lower-limb muscles) or placebo. Post hoc analysis assessed the impact of muscle selection patterns on ankle Modified Ashworth Scale and physician-assessed Clinical Global Impression of Change based on change from baseline to average of weeks 4/6 versus placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PHM.0000000000001101DOI Listing
May 2019
1 Read

Chinese Herbal Medicine for Wilson's Disease: A Systematic Review and Meta-Analysis.

Front Pharmacol 2019 29;10:277. Epub 2019 Mar 29.

Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.

Wilson's disease (WD) is a rare autosomal recessive inherited disorder of chronic copper toxicosis. Currently, Chinese herbal medicines (CHM) is widely used for WD. Here, we conducted an updated systematic review to investigate the efficacy and safety of CHM for WD and its possible mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.00277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455065PMC
March 2019
3 Reads

Epidemiology and treatment of multiple sclerosis in elderly populations.

Nat Rev Neurol 2019 Apr 18. Epub 2019 Apr 18.

Jacobs Multiple Sclerosis Center for Treatment and Research, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, State University of New York (SUNY), Buffalo, NY, USA.

The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing owing to increased longevity of the general population and the availability of effective disease-modifying therapies. However, ageing presents unique challenges in patients with MS largely as a result of their increased frequency of age-related and MS-related comorbidities as well as transition of the disease course from an inflammatory to a neurodegenerative phenotype. Immunosenescence (the weakening of the immune system associated with natural ageing) might be at least partly responsible for this transition, which further complicates disease management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0183-3DOI Listing
April 2019
2 Reads

Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol.

Syst Rev 2019 Apr 18;8(1):99. Epub 2019 Apr 18.

Department of Medicine, University of Ottawa and The Ottawa Hospital Research Institute, 1053 Carling Avenue, Ottawa, ON, K1Y 4E9, Canada.

Background And Purpose: Cerebral venous thrombosis causes disability from venous infarct and hemorrhage and potential mortality. Anticoagulation improves survival and disability outcomes, yet direct oral anticoagulants are currently not indicated in cerebral venous thrombosis due to lack of evidence, despite being on the market for nearly a decade. This systematic review will collate evidence of reported safety and efficacy of direct oral anticoagulant therapy in cerebral venous thrombosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13643-019-1022-8DOI Listing

[Mechanical thrombectomy treatment in patients with acute ischemic stroke: a single center study].

Beijing Da Xue Xue Bao Yi Xue Ban 2019 Apr;51(2):256-259

Department of Interventional Radiologyand Vascular Surgery, Peking University Third Hospital, Beijing 100191, China.

Objective: To evaluate the effectiveness and safety of mechanical thrombectomy treatment in patients with acute ischemic stroke (AIS),and to explore influential factors of the clinical prognosis preliminarily.

Methods: Clinical data of 26 patients with acute cerebral arterial occlusion treated with mechanical thrombectomy in Peking University Third Hospital from January 2014 to June 2017 were retrospectively collected. The immediate effects of the 26 patients in this group after mechanical thrombectomy treatment were analyzed,The national institutes of health stroke scale (NIHSS) scores between preoperative and at discharge of the 26 patients in this group were compared,and modified Rankin scale (mRS) scores of 90 days post operation were analyzed to assess the prognosis of the 26 patients in this group. Read More

View Article

Download full-text PDF

Source
April 2019
1 Read

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers.

Drug Des Devel Ther 2019 29;13:1011-1022. Epub 2019 Mar 29.

Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Republic of Korea,

Background: KM-819 is a novel FAS-associated factor 1 (FAF1) inhibitor, and a neuroprotective agent, under clinical development for the treatment of Parkinson's disease as a disease-modifying drug.

Methods: This first-in-human, single and multiple ascending dose study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 in healthy volunteers. Additionally, the effect of age on safety and pharmacokinetics were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S198753DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445238PMC
March 2019
1 Read

The Efficacy and Safety of Prochlorperazine in Patients With Acute Migraine: A Systematic Review and Meta-Analysis.

Headache 2019 Apr 16. Epub 2019 Apr 16.

Department of Emergency Medicine, Orthopedic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Objective: The aim of this review was to evaluate the efficacy and safety of prochlorperazine (PCP) in patients with acute migraine headache in the emergency department (ED).

Methods: Electronic databases (Medline, Scopus, Web of Science, and Cochrane) were searched for randomized clinical trials that investigated the effect of PCP on headache relief. The outcomes were the number of patients without headache or with reduced headache severity, the number of adverse events, and the need for rescue analgesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/head.13527DOI Listing
April 2019
2 Reads

Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis.

Am J Alzheimers Dis Other Demen 2019 Apr 15:1533317519843720. Epub 2019 Apr 15.

1 Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.

Aim: To assess the efficacy and safety of intravenous immunoglobulin (IVIg) for patients with Alzheimer's disease (AD).

Materials And Methods: We searched electronic databases and other sources for randomized controlled trials comparing IVIg with placebo or other treatment for adults with AD. Primary outcome was change from baseline in Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1533317519843720DOI Listing

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.

Mult Scler 2019 Apr 15:1352458519841829. Epub 2019 Apr 15.

School of Medicine, University of Cambridge, Cambridge, UK.

Background: Autoimmune disorders including nephropathies have been reported more frequently in alemtuzumab-treated multiple sclerosis (MS) patients than in the general population.

Objective: Describe instances of autoimmune nephropathy in alemtuzumab-treated MS patients.

Methods: Cases were identified from safety monitoring within the alemtuzumab relapsing-remitting multiple sclerosis (RRMS) clinical development program (CDP) or post-marketing, or following off-label use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458519841829DOI Listing
April 2019
2 Reads

Prolonged Response Induced by Single Agent Vemurafenib in a Spinal Ganglioglioma: A Case Report and Review of the Literature.

Front Oncol 2019 26;9:177. Epub 2019 Mar 26.

Department of Medical Oncology, University Hospital of Besançon, Besançon, France.

Spinal ganglioglioma is a rare low-grade, slow-growing tumor of the central nervous system affecting mostly children and young adults. After surgery, some patients show tumor recurrence and/or malignant transformation. Gangliogliomas harbor molecular deficiencies such as mutations in the B-rapidly accelerated fibrosarcoma () gene, resulting in activation of a downstream signaling pathway and cancer development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2019.00177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448025PMC

Safety and Efficacy of Heparinization During Mechanical Thrombectomy in Acute Ischemic Stroke.

Front Neurol 2019 29;10:299. Epub 2019 Mar 29.

Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

The benefits of heparization during mechanical thrombectomy (MT) with newer generation thrombectomy devices, and if it is counterbalanced by the increased risk of intracranial hemorrhage (ICH) remain unknown. We included eligible patients who underwent MT from the ANGEL registry study (2015-2017) in China. Subjects in the current analysis were dichotomized into two groups according to whether adequate heparinization during MT was performed. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fneur.2019.00299
Publisher Site
http://dx.doi.org/10.3389/fneur.2019.00299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450216PMC
March 2019
2 Reads

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Cephalalgia 2019 Apr 13:333102419835459. Epub 2019 Apr 13.

7 Amgen Inc., Thousand Oaks, CA, USA.

Background: Erenumab was effective and well tolerated in a pivotal clinical trial of episodic migraine that included subjects both naïve to, and those who had failed, previous preventives. Here we evaluated the efficacy and safety of erenumab (70 mg or 140 mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s): ≥1 or ≥2 prior failed migraine preventive categories, and in patients who had never failed.

Methods: Prespecified subgroup analyses evaluated change from baseline to months 4-6 (the primary endpoint of the blinded study phase) in monthly migraine days, achievement of ≥50% and ≥75% reduction in monthly migraine days, and change from baseline in acute migraine-specific medication days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419835459DOI Listing
April 2019
2 Reads

Length-dependent truncal Aδ-fiber dysfunction in hereditary transthyretin amyloidosis: An intra-epidermal electrical stimulation study.

Clin Neurophysiol 2019 Mar 23;130(6):903-910. Epub 2019 Mar 23.

Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan; Institute for Biomedical Sciences, Shinshu University, Matsumoto, Japan.

Objective: To elucidate Aδ-fiber dysfunction at the trunk in patients with hereditary transthyretin (ATTRm) amyloidosis using intra-epidermal electrical stimulation (IES).

Methods: In 16 patients with ATTRm amyloidosis and 18 healthy subjects, sensory thresholds using IES and cooling detection thresholds using the Computer-Aided Sensory Evaluation (CASE IV) system, were assessed to investigate Aδ-fiber functions at the Th10 level of the anterior, lateral, and posterior trunk. Furthermore, evoked potentials (EPs) following electrical stimulation using IES at the anterior and posterior trunk were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinph.2019.03.007DOI Listing

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.

Headache 2019 Apr 12. Epub 2019 Apr 12.

Teva Pharmaceuticals, Frazer, PA, USA.

Objective: Presentation of pooled analysis of safety data for fremanezumab in patients with chronic (CM) or episodic migraine (EM) from 4 placebo-controlled phase 2b and phase 3 studies.

Background: There is a need for an effective, safe, and well-tolerated preventive therapy that specifically targets the pathophysiology of migraine to reduce the frequency and severity of migraine attacks in patients with CM or EM who experience 4 or more migraine days per month. Fremanezumab is a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, a neuropeptide involved in the pathophysiology of migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/head.13534DOI Listing
April 2019
1 Read

Carotid artery stenting in acute stroke using a microporous stent device: a single centre experience.

World Neurosurg 2019 Apr 8. Epub 2019 Apr 8.

Interventional Radiology Service - Department of Radiology, Austin Hospital, Melbourne, Australia; Department of Neurology, Austin Health, Melbourne, Australia; Department of Imaging - Monash Health, Melbourne, Australia; Interventional Neuroradiology Service - Department of Radiology, Austin Hospital, Melbourne, Australia; School of Medicine - Faculty of Health, Deakin University, Waurn Ponds, Australia.

Background: Carotid artery stenting (CAS) is an established treatment for carotid artery stenosis, typically in a semi-elective or elective setting. The growth of mechanical thrombectomy for acute stroke has led to an increased use of emergent carotid artery stenting (eCAS). This single-centre retrospective case series evaluates the safety and efficacy of eCAS using a dual-layer micromesh nitinol stent to treat carotid artery stenosis in the acute stroke setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.04.024DOI Listing
April 2019
3 Reads
2.417 Impact Factor

Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling.

Biomed Rep 2019 Apr 5;10(4):218-224. Epub 2019 Mar 5.

Department of Neurology, University Hospital Zurich, CH-8091 Zurich, Switzerland.

Constitutive activation of Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic event in certain types of human cancer and is associated with poor patient survival. Small molecule signaling inhibitors have improved the clinical outcomes of patients with various cancer types but attempts to target KRAS have been unsuccessful. Plinabulin represents a novel class of agents that inhibit tubulin polymerization with a favorable safety profile in clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/br.2019.1196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439430PMC

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis.

Front Neurol 2019 27;10:293. Epub 2019 Mar 27.

Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.

Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of vasospasm in patients with subarachnoid hemorrhage with a favorable safety profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446974PMC
March 2019
1 Read

Safety and tolerability of Vitamin D3 5000 IU/day in epilepsy.

Epilepsy Behav 2019 Apr 7;94:195-197. Epub 2019 Apr 7.

Department of Neurology, UCLA School of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, USA.

Purpose: Preclinical and early clinical research indicates that Vitamin D3 may reduce seizures in both animal models and open-label clinical trials.

Methods: This is an initial report of an ongoing pilot study of oral Vitamin D3 5000 IU/day in subjects with drug-resistant epilepsy. After Institutional Review Board (IRB) approval and informed consent, subjects with ;less than one focal onset or generalized tonic-clonic seizure per month were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2019.03.001DOI Listing
April 2019
1 Read

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.

Ther Adv Neurol Disord 2019 1;12:1756286419836571. Epub 2019 Apr 1.

Department of Neurology with Institute of Translational Neurology, University of Münster, Building A1, Albert Schweitzer Campus 1, 48149 Münster, Germany.

In recent years, there has been a paradigm shift in the treatment of multiple sclerosis (MS) owing to the approval of a number of new drugs with very distinct mechanisms of action. All approved disease-modifying drugs primarily work directly on the immune system. However, the identification of an 'optimal choice' for individual patients with regard to treatment efficacy, treatment adherence and side-effect profile has become increasingly complex including conceptual as well as practical considerations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286419836571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444778PMC
April 2019
4 Reads

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Front Neurol 2019 22;10:253. Epub 2019 Mar 22.

Rehabilitation & MS-Centre Overpelt, Hasselt University, Hasselt, Belgium.

Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive days 12 months later), resulted in significantly greater improvements in clinical and MRI outcomes vs. subcutaneous interferon beta-1a over 2 years in patients with active relapsing-remitting MS (RRMS) who were either treatment-naive (CARE-MS I; NCT00530348) or had an inadequate response to prior therapy (CARE-MS II; NCT00548405). Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fneur.2019.00253
Publisher Site
http://dx.doi.org/10.3389/fneur.2019.00253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439479PMC
March 2019
4 Reads

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.

Proc Natl Acad Sci U S A 2019 Apr 8;116(17):8463-8470. Epub 2019 Apr 8.

Center of Neuroimmunology, Institut d'Investigacions Biomediques August Pi Sunyer, 08036 Barcelona, Spain;

There are adaptive T-cell and antibody autoimmune responses to myelin-derived peptides in multiple sclerosis (MS) and to aquaporin-4 (AQP4) in neuromyelitis optica spectrum disorders (NMOSDs). Strategies aimed at antigen-specific tolerance to these autoantigens are thus indicated for these diseases. One approach involves induction of tolerance with engineered dendritic cells (tolDCs) loaded with specific antigens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1820039116DOI Listing
April 2019
1 Read

Childhood trauma history is linked to abnormal brain connectivity in major depression.

Proc Natl Acad Sci U S A 2019 Apr 8;116(17):8582-8590. Epub 2019 Apr 8.

Center for Neuromodulation in Depression and Stress, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104;

Patients with major depressive disorder (MDD) present with heterogeneous symptom profiles, while neurobiological mechanisms are still largely unknown. Brain network studies consistently report disruptions of resting-state networks (RSNs) in patients with MDD, including hypoconnectivity in the frontoparietal network (FPN), hyperconnectivity in the default mode network (DMN), and increased connection between the DMN and FPN. Using a large, multisite fMRI dataset ( = 189 patients with MDD, = 39 controls), we investigated network connectivity differences within and between RSNs in patients with MDD and healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1900801116DOI Listing
April 2019
8 Reads

Safety and Efficacy of Erythrocyte Encapsulated Thymidine Phosphorylase in Mitochondrial Neurogastrointestinal Encephalomyopathy.

J Clin Med 2019 Apr 5;8(4). Epub 2019 Apr 5.

Molecular and Clinical Sciences, St. George's, University of London, London, SW17 ORE, UK.

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an ultra-rare autosomal recessive disorder of nucleoside metabolism that is caused by mutations in the nuclear thymidine phosphorylase gene () gene, encoding for the enzyme thymidine phosphorylase. There are currently no approved treatments for MNGIE. The aim of this study was to investigate the safety, tolerability, and efficacy of an enzyme replacement therapy for the treatment of MNGIE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8040457DOI Listing

The influence of mean arterial pressure on the efficacy and safety of dual antiplatelet therapy in minor stroke or transient ischemic attack patients.

J Clin Hypertens (Greenwich) 2019 Apr 7. Epub 2019 Apr 7.

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Mean arterial pressure (MAP) is the strongest predictor of stroke. The combination of clopidogrel and aspirin within 24 hours after onset has been suggested by the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) study to be superior to aspirin alone. However, it is not clear whether poststroke blood pressure has an influence on the efficacy and safety of dual antiplatelet treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jch.13527DOI Listing
April 2019
1 Read

Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.

Authors:
M Scott Perry

Epilepsy Curr 2019 Mar-Apr;19(2):93-95

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Devinsky O, Patel AD, Cross JH, et al; GWPCARE3 Study Group. N Engl J Med. 2018;378:1888-1897. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1535759719835671DOI Listing
April 2019
7 Reads

A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan.

Adv Ther 2019 Apr 5. Epub 2019 Apr 5.

Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

Introduction: Rivastigmine is a cholinesterase inhibitor, approved for the treatment of mild-to-moderate dementia of Alzheimer's type. This study assessed the short- and long-term effectiveness and safety of rivastigmine in patients with mild-to-moderate Alzheimer's disease (AD) in a real-world clinical setting in Taiwan.

Methods: This was a 48-week, single-arm, open-label, prospective, observational, post-marketing surveillance, multicenter study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12325-019-00939-0DOI Listing
April 2019
3 Reads

Natalizumab-associated progressive multifocal leukoencephalopathy in Germany.

Neurology 2019 Apr 5. Epub 2019 Apr 5.

From the Department Safety of Medicinal Products and Medical Devices (K.B., B.K.-S.), and Section Biostatistics (B.H.), Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen; Clinic of Neurology with Institute of Translational Neurology (N.S.), University Hospital Muenster, University Muenster; Institute for Virology (O.A.), University of Duesseldorf, Medical Faculty, Duesseldorf; and Department of Neurology (C.W.), University Hospital Koeln, Germany.

Objective: To evaluate characteristics relevant to diagnosis of JC polyomavirus-associated progressive multifocal leukoencephalopathy (PML), and PML risk stratification in a large national cohort of patients with multiple sclerosis during therapy with natalizumab.

Methods: Analysis of 292 adverse drug reaction forms on suspected cases of PML reported to the German national competent authority until July 2017. Patients not fulfilling PML diagnostic criteria or with insufficient information available were excluded. Read More

View Article

Download full-text PDF

Source
http://www.neurology.org/lookup/doi/10.1212/WNL.000000000000
Publisher Site
http://dx.doi.org/10.1212/WNL.0000000000007451DOI Listing
April 2019
4 Reads

Endovascular Thrombolysis or Thrombectomy for Cerebral Venous Thrombosis: Study of Nationwide Inpatient Sample 2004-2014.

J Stroke Cerebrovasc Dis 2019 Apr 2. Epub 2019 Apr 2.

Department of Neurology, Academic Medical Center, Netherlands.

Background And Purpose: 15% of cerebral venous thrombosis (CVT) patients have poor outcomes despite anticoagulation. Uncontrolled studies suggest that endovascular approaches may benefit such patients. In this study, we analyze Nationwide Inpatient Sample (NIS) data to evaluate the safety and efficacy of endovascular therapy (ET) versus medical management in CVT. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10523057193012
Publisher Site
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2019.03.025DOI Listing
April 2019
2 Reads

Mechanical thrombectomy with a novel stent retriever with multifunctional zones: Initial clinical experience with the NeVa™ thrombectomy device.

J Neuroradiol 2019 Apr 2. Epub 2019 Apr 2.

Department of Neuroradiology, Vall d'Hebron University Hospital, Barcelona, Spain.

Background And Purpose: The NeVa™ (Vesalio, Nashville, Tennessee) thrombectomy device is a CE-approved novel hybrid-cell stent retriever with offset enlarged openings coupled with functional zones and a closed distal end. The device was designed to incorporate and trap resistant emboli. The purpose was to determine the safety and efficacy of the NeVa™ stent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurad.2019.03.007DOI Listing
April 2019
1 Read

One-year single-center experience with the Aperio thrombectomy device in large vessel occlusion in the anterior circulation: safety, efficacy, and clinical outcome.

Neurol Sci 2019 Apr 4. Epub 2019 Apr 4.

Medical Faculty, Department of Diagnostic and Interventional Radiology, University Duesseldorf, Moorenstr.5, 40225, Duesseldorf, Germany.

Background And Purpose: The Aperio thrombectomy device (Aperio) is a stent retriever designed to achieve rapid and substantial flow restoration in acute ischemic stroke due to large-vessel occlusions (LVOs). We evaluated the safety and efficacy of the Aperio device and compared it with published data of established stent retrievers.

Methods: We retrospectively analyzed institutional data of consecutive stroke procedures in patients with LVO in the anterior circulation that were treated between January 2017 and December 2017 with the Aperio. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10072-019-03861-zDOI Listing
April 2019
1 Read

Vestibular evoked myogenic potentials in practice: Methods, pitfalls and clinical applications.

Clin Neurophysiol Pract 2019 26;4:47-68. Epub 2019 Feb 26.

Neurology Department and Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Camperdown, Australia.

Vestibular evoked myogenic potentials (VEMPs) are a useful and increasingly popular component of the neuro-otology test battery. These otolith-dependent reflexes are produced by stimulating the ears with air-conducted sound or skull vibration and recorded from surface electrodes placed over the neck (cervical VEMPs) and eye muscles (ocular VEMPs). VEMP abnormalities have been reported in various diseases of the ear and vestibular system, and VEMPs have a clear role in the diagnosis of superior semicircular canal dehiscence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cnp.2019.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430081PMC
February 2019
6 Reads

First seizure presentations in adults: beyond assessment and treatment.

J Neurol Neurosurg Psychiatry 2019 Apr 4. Epub 2019 Apr 4.

Neurology, Alfred Health, Melbourne, Victoria, Australia.

Almost 10% of people will experience at least one seizure over a lifetime. Although common, first seizures are serious events and warrant careful assessment and management. First seizures may be provoked by acute or remote symptomatic factors including life-threatening metabolic derangements, drug toxicity or structural brain lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2018-320215DOI Listing
April 2019
3 Reads

Progress on the development of rapid diagnostic tests for foodborne neglected zoonotic helminthiases: A systematic review.

Acta Trop 2019 Apr 1;194:135-147. Epub 2019 Apr 1.

Department of Veterinary Public Health and Food Safety, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.

Background: Foodborne Neglected Zoonotic Helminths (FNZH) are parasites of both economic and public health importance. They include Taenia solium, Echinococcus granulosus sensu lato, Echinococcus multilocularis and Foodborne trematodes (FBT). FNZH are earmarked for major interventions for control, elimination and eradication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.actatropica.2019.03.030DOI Listing
April 2019
1 Read
2.270 Impact Factor

Comparative efficacy and safety of bridging strategies with direct mechanical thrombectomy in large vessel occlusion: A systematic review and meta-analysis.

Medicine (Baltimore) 2019 Apr;98(14):e14956

Department of Neurology, Baotou Central Hospital, Baotou, Inner Mongolia, China.

Background: Whether bridging strategies[intravenous thrombolysis (IVT) + mechanical thrombectomy (MT)] are superior to mechanical thrombectomy alone for large vessel occlusion(LVO) is still uncertain. A systematic review and meta-analysis was conducted to investigate and evaluate comparative efficacy and safety of bridging strategies vs direct MT in patients with LVO.

Methods: The PubMed, EMBASE and Cochrane library databases were searched to evaluate the efficacy and safety of bridging strategies with direct MT in LVO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014956DOI Listing
April 2019
1 Read
5.723 Impact Factor

A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab.

J Chin Med Assoc 2019 Apr;82(4):265-271

General Clinical Research Center, Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan, ROC.

Background: Alirocumab can provide significant reductions in low-density lipoprotein cholesterol (LDL-C). However, data regarding its efficacy and safety in Asians are limited.

Methods: A subgroup analysis of Taiwanese patients (n = 116) in a randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT, clinicaltrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JCMA.0000000000000062DOI Listing
April 2019
4 Reads

Should We Use Tegaserod for Irritable Bowel Syndrome?

Am J Ther 2019 Mar 29. Epub 2019 Mar 29.

Department of Neurology, Stroke Unit, Johns Hopkins University, Towson, MD.

Background: Tegaserod, a serotonin (5-HT4) agonist initially approved for constipation but withdrawn from use in 2007 because of concerns about cardiovascular adverse effects, was resubmitted to the Food and Drug Administration (FDA) in 2018 for use in a restricted population.

Areas Of Uncertainty: Despite an 18-year regulatory history, there remain pharmacology and clinical trial concerns that have not been addressed but are critical for proper assessment of the drug safety and efficacy profile.

Sources: Original FDA reviews, FDA and developer advisory committee briefing documents, and published literature. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00045391-900000000-9847
Publisher Site
http://dx.doi.org/10.1097/MJT.0000000000000947DOI Listing
March 2019
3 Reads

Highly-calcific carotid lesions endovascular management in symptomatic and increased-stroke-risk asymptomatic patients using the CGuard™ dual-layer carotid stent system: Analysis from the PARADIGM study.

Catheter Cardiovasc Interv 2019 Apr 3. Epub 2019 Apr 3.

Department of Cardiac & Vascular Diseases, John Paul II Hospital, Jagiellonian University Medical College, Krakow, Poland.

Objectives: To assess feasibility, safety, angiographic, and clinical outcome of highly-calcific carotid stenosis (HCCS) endovascular management using CGuard™ dual-layer carotid stents.

Background: HCCS has been a challenge to carotid artery stenting (CAS) using conventional stents. CGuard combines a high-radial-force open-cell frame conformability with MicroNet sealing properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccd.28219DOI Listing
April 2019
1 Read

Outcome, efficacy and safety of endovascular thrombectomy in ischaemic stroke according to time to reperfusion: data from a multicentre registry.

Ther Adv Neurol Disord 2019 27;12:1756286419835708. Epub 2019 Mar 27.

Department of Neurology, University Hospital Bern, Inselspital, University of Bern, Freiburgstrasse 8, CH-3010, Switzerland.

Background And Purpose: In acute ischaemic stroke (AIS) of the anterior circulation (AC) treated with mechanical thrombectomy (MT), data point to a decline of treatment effect with increasing time from symptom onset to treatment. However, the magnitude of the decline will depend on the clinical setting and imaging selection used. The aims of this study were (1) to evaluate the clinical effect of time to reperfusion (TTR); and (2) to assess the safety and technical efficacy of MT according to strata of TTR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286419835708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437320PMC
March 2019
3 Reads

Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study.

Ther Adv Neurol Disord 2019 27;12:1756286419835077. Epub 2019 Mar 27.

Department of Neurology, Bern University Hospital, University of Bern, Switzerland.

Background: Teriflunomide is a once-daily oral immunomodulatory agent approved for the treatment of relapsing-remitting multiple sclerosis (MS). We aimed to obtain data on the effectiveness, tolerability, and subject satisfaction with teriflunomide (Aubagio®) under clinical practice conditions in unselected MS patients.

Methods: This work was a non-interventional, prospective, longitudinal, observational study in 307 sites in Germany. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286419835077DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437319PMC
March 2019
4 Reads

Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset.

Stroke 2019 May;50(5):1149-1155

From the Department of Clinical Neurosciences, Karolinska Institutet and Department of Neurology Karolinska University Hospital, Stockholm, Sweden (C.C., M.M., N.A.).

Background and Purpose- There are limited data on intravenous thrombolysis treatment in patients with ischemic stroke who have received prophylactic doses of low molecular weight heparins (LMWHs). We aimed to evaluate the safety and outcomes of intravenous thrombolysis treatment in stroke patients taking thromboprophylactic doses of LMWH. Methods- We analyzed 109 291patients treated with intravenous thrombolysis, recorded in the Safe Implementation of Treatments in Stroke International Thrombolysis Register between 2003 and 2017 not taking oral anticoagulants or therapeutic doses of heparin at stroke onset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.024575DOI Listing
May 2019
3 Reads